Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse.

Emilie Thivat 1, 2, 3, * Sophie Thérondel 2, 4 Olivier Lapirot 1, 2 Catherine Abrial 1, 2, 3 Pierre Gimbergues 2, 5 Emilie Gadéa 1, 2 Eloïse Planchat 1, 2, 3 Fabrice Kwiatkowski 1, 2 Marie Mouret-Reynier 3, 4 Philippe Chollet 1, 2, 3, 4 Xavier Durando 2, 3, 4
* Auteur correspondant
1 Centre Jean Perrin
2 CIC - Clermont Ferrand
3 IMTV - Imagerie Moléculaire et Thérapie Vectorisée
4 Oncology department
5 Surgery department
Abstract : BACKGROUND: Weight change during chemotherapy is reported to be associated with a worse prognosis in breast cancer patients, both with weight gain and weight loss. However, most studies were conducted prior to the common use of anthracycline-base chemotherapy and on North American populations with a mean BMI classified as overweight. Our study was aimed to evaluate the prognostic value of weight change during anthracycline-based chemotherapy on non metastatic breast cancer (European population) with a long term follow-up. METHODS: Patients included 111 women diagnosed with early stage breast cancer and locally advanced breast cancer who have been treated by anthracycline-based chemotherapy regimen between 1976 and 1989. The relative percent weight variation (WV) between baseline and postchemotherapy treatment was calculated and categorized into either weight change (WV > 5%) or stable (WV < 5%). The median follow-up was 20.4 years [19.4 - 27.6]. Cox proportional hazard models were used to evaluate any potential association of weight change and known prognostic factors with the time to recurrence and overall survival. RESULTS: Baseline BMI was 24.4 kg/m2 [17.1 - 40.5]. During chemotherapy treatment, 31% of patients presented a notable weight variation which was greater than 5% of their initial weight.In multivariate analyses, weight change (> 5%) was positively associated with an increased risk of both recurrence (RR 2.28; 95% CI: 1.29-4.03) and death (RR 2.11; 95% CI: 1.21-3.66). CONCLUSIONS: Our results suggest that weight change during breast-cancer chemotherapy treatment may be related to poorer prognosis with higher recurrence and higher mortality in comparison to women who maintained their weight.
Type de document :
Article dans une revue
BMC Cancer, BioMed Central, 2010, 10 (1), pp.648. 〈10.1186/1471-2407-10-648〉
Liste complète des métadonnées

Littérature citée [45 références]  Voir  Masquer  Télécharger
http://www.hal.inserm.fr/inserm-00663871
Contributeur : Ed. Bmc <>
Soumis le : vendredi 27 janvier 2012 - 17:07:45
Dernière modification le : jeudi 14 décembre 2017 - 12:20:36
Document(s) archivé(s) le : lundi 19 novembre 2012 - 15:17:51

Fichiers

1471-2407-10-648.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

PRES_CLERMONT | IMTV | ACL-SVSAE | CJP | FNCLCC | IMOST

Citation

Emilie Thivat, Sophie Thérondel, Olivier Lapirot, Catherine Abrial, Pierre Gimbergues, et al.. Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse.. BMC Cancer, BioMed Central, 2010, 10 (1), pp.648. 〈10.1186/1471-2407-10-648〉. 〈inserm-00663871〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

923

Téléchargements de fichiers

283

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD